NASDAQ:IONS

Ionis Pharmaceuticals Stock Forecast, Price & News

$37.73
+1.36 (+3.74 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.03
$37.85
50-Day Range
$34.54
$40.05
52-Week Range
$34.43
$64.37
Volume876,124 shs
Average Volume1.43 million shs
Market Capitalization$5.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
30 days | 90 days | 365 days | Advanced Chart
Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals logo

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

676th out of 2,210 stocks

Pharmaceutical Preparations Industry

345th out of 867 stocks

Analyst Opinion: 3.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ionis Pharmaceuticals?

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 8,970,000 shares, a decline of 17.3% from the May 31st total of 10,850,000 shares. Based on an average trading volume of 1,820,000 shares, the short-interest ratio is presently 4.9 days. Approximately 6.7% of the shares of the company are sold short.
View Ionis Pharmaceuticals' Short Interest
.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Ionis Pharmaceuticals
.

How can I listen to Ionis Pharmaceuticals' earnings call?

Ionis Pharmaceuticals will be holding an earnings conference call on Wednesday, August 4th at 11:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.16. The business had revenue of $112 million for the quarter, compared to analyst estimates of $134.93 million. Ionis Pharmaceuticals had a negative net margin of 69.63% and a negative trailing twelve-month return on equity of 41.74%. The firm's quarterly revenue was down 15.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.35) EPS.
View Ionis Pharmaceuticals' earnings history
.

How has Ionis Pharmaceuticals' stock been impacted by Coronavirus?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IONS stock has decreased by 23.2% and is now trading at $37.73.
View which stocks have been most impacted by COVID-19
.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $600 M-, compared to the consensus revenue estimate of $632.68 million.

What price target have analysts set for IONS?

15 equities research analysts have issued 1-year price objectives for Ionis Pharmaceuticals' stock. Their forecasts range from $33.00 to $86.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $57.86 in the next year. This suggests a possible upside of 53.4% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:
  • Brett P. Monia, Chief Executive Officer & Director
  • Joel Edwards, Vice President-Corporate & Commercial Operations
  • Elizabeth L. Hougen, Chief Financial Officer & Executive VP-Finance
  • C. Frank Bennett, Chief Scientific Officer & Executive VP
  • Sanjay Bhanot, Chief Medical Officer

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DAVENPORT & Co LLC (0.08%), Grandfield & Dodd LLC (0.01%) and Heritage Wealth Advisors (0.00%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals
.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was bought by a variety of institutional investors in the last quarter, including Grandfield & Dodd LLC, and Heritage Wealth Advisors.
View insider buying and selling activity for Ionis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $37.73.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $5.32 billion and generates $729 million in revenue each year. The company earns $-451,290,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 147,000 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Where are Ionis Pharmaceuticals' headquarters?

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at (760) 931-9200 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.